CYP19A1 and osteoporosis: There were 60 DRPs concerning osteoporosis risk, with the drug class most often involved being proton-pump inhibitors (PPIs) (39, 65.0%), followed by corticosteroids (11, 18.3%), anti-epileptics (4, 6.7%), gonadotropin releasing hormone analogues (2, 3.3%), aromatase inhibitors (2, 3.3%), other hormone antagonists and related agents (1, 1.7%), and thiazolidinediones (1, 1.7%).